|1.||Lin, Xi: 4 articles (10/2012 - 06/2005)|
|2.||Qiu, Peng-xin: 3 articles (10/2012 - 06/2005)|
|3.||Yan, Guang-mei: 3 articles (10/2012 - 06/2005)|
|4.||Chen, Jia-shu: 3 articles (10/2012 - 06/2005)|
|5.||Chu, Arthur J: 3 articles (03/2006 - 08/2005)|
|6.||Liang, Xiu-xia: 2 articles (02/2011 - 06/2005)|
|7.||Chen, Qi: 2 articles (11/2007 - 06/2005)|
|8.||Grandone, E: 2 articles (06/2001 - 11/2000)|
|9.||Margaglione, M: 2 articles (06/2001 - 11/2000)|
|10.||Brancaccio, V: 2 articles (06/2001 - 11/2000)|
05/24/2011 - "Through exosite engagement, GPIbα may influence FIIa-dependent processes relevant to hemostasis and thrombosis."
03/01/2006 - "Bimodal FIIa inhibitory activity of ATH was demonstrated in animal models of venous and arterial thrombosis, but is in need of further development. "
06/01/2005 - "In vivo, UK 40 kU/kg and FIIa 1.0 mg/kg reduced the weight of residual thrombus to 9.0+/-2.5 mg and 7.8+/-3.5 mg compared with negative control group (30.0+/-5.4 mg). "
02/01/2015 - "EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis."
01/01/2006 - "TF hypercoagulablility directly contributes to thrombus formation resulting from the major events of fibrin deposition and FIIa-induced platelet activation/aggregation. "
04/01/2015 - "Forrest classification in 6 patients an active bleeding was revealed (FIa, FIb), in 11--nonstable hemostasis (FIIa, FIIb, FIIc), and in 22--FIII. "
01/01/2013 - "Management of bleeding in patients taking FXa and FIIa inhibitors."
11/01/2012 - "In cases of bleeding or thromboembolic events under treatment, targeted monitoring of drug concentration or anti-FXa- or anti-FIIa-activity may be helpful to identify the underlying cause. "
05/01/2001 - "It shows that FIIa from Agkistrodon acutus venom is able to solubilize thrombus in vivo without hemorrhage at an effective dose for thrombolysis."
11/01/2009 - "We investigated anti-FXa- and anti-FIIa-activity, thrombin generation (ETP), tissue factor pathway inhibitor (TFPI) - and D-dimer in patients exhibiting high bleeding risk in early neurological rehabilitation over 2 months in an observational study. "
|4.||Pulmonary Fibrosis (Hamman Rich Syndrome)
|5.||Disseminated Intravascular Coagulation
11/01/2007 - "In this study, we evaluated the effect of FII(a) on lipopolysaccharide (LPS)-induced experimental disseminated intravascular coagulation (DIC) in rabbits, through the continuous infusion of 100-microg/kg/h LPS for a period of 6 h. "
11/01/2007 - "The effect of fibrinolytic enzyme FIIa from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits."
|6.||Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)
|7.||lipoprotein-associated coagulation inhibitor (TFPI)
|8.||fibrin fragment D (D-dimer)
|3.||Heterologous Transplantation (Xenotransplantation)